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Receptor-Specific Regulation of Phosphatidylinositol 3-Kinase
Activation by the Protein Tyrosine Phosphatase Shp2
Si Qing Zhang,1 William G. Tsiaras,1 Toshiyuki Araki,1 Gengyun Wen,1 Liliana Minichiello,2†
Ruediger Klein,2‡ and Benjamin G. Neel1*
Cancer Biology Program, Division of Hematology-Oncology, Department of Medicine, Beth Israel-Deaconess Medical Center,
and Harvard Medical School, Boston, Massachusetts 02115,1 and Developmental Biology Program,
European Molecular Biology Laboratory, 69117 Heidelberg, Germany2
Received 6 November 2001/Returned for modification 7 January 2002/Accepted 14 March 2002
Receptor tyrosine kinases (RTKs) play distinct roles in multiple biological systems. Many RTKs transmit
similar signals, raising questions about how specificity is achieved. One potential mechanism for RTK
specificity is control of the magnitude and kinetics of activation of downstream pathways. We have found that
the protein tyrosine phosphatase Shp2 regulates the strength and duration of phosphatidylinositol 3-kinase
(PI3K) activation in the epidermal growth factor (EGF) receptor signaling pathway. Shp2 mutant fibroblasts
exhibit increased association of the p85 subunit of PI3K with the scaffolding adapter Gab1 compared to that
for wild-type (WT) fibroblasts or Shp2 mutant cells reconstituted with WT Shp2. Far-Western analysis
suggests increased phosphorylation of p85 binding sites on Gab1. Gab1-associated PI3K activity is increased
and PI3K-dependent downstream signals are enhanced in Shp2 mutant cells following EGF stimulation.
Analogous results are obtained in fibroblasts inducibly expressing dominant-negative Shp2. Our results
suggest that, in addition to its role as a positive component of the Ras-Erk pathway, Shp2 negatively regulates
EGF-dependent PI3K activation by dephosphorylating Gab1 p85 binding sites, thereby terminating a previ-
ously proposed Gab1-PI3K positive feedback loop. Activation of PI3K-dependent pathways following stimula-
tion by other growth factors is unaffected or decreased in Shp2 mutant cells. Thus, Shp2 regulates the kinetics
and magnitude of RTK signaling in a receptor-specific manner.
Receptor tyrosine kinases (RTKs) play critical roles in the
regulation of cell growth, motility, differentiation, and death
(12, 37). There are a large number of RTKs, and genetic
analyses reveal that they have profoundly different biological
effects. However, RTK signaling mechanisms are remarkably
similar (28, 37). Ligand binding causes receptor dimerization,
kinase activation, and trans-phosphorylation of the RTK on
multiple tyrosyl residues. These phosphotyrosines serve as
docking sites for the recruitment of a variety of signal relay
molecules that contain Src homology 2 (SH2) or phosphoty-
rosine binding (PTB) domains, leading to the activation of
multiple downstream signaling pathways. Some receptors also
employ scaffolding adapter molecules, which appear to amplify
receptor signals (28). Typically, scaffolding adapters are com-
prised of a membrane-targeting motif (typically a pleckstrin
homology [PH] and often a PTB domain) and multiple addi-
tional binding sites for SH2- and/or PTB domain-containing
proteins. Some differences in RTK biological effects may be
explained by differential utilization of signal relay molecules.
However, many RTKs utilize the same (or a similar) panoply
of signal relay molecules-scaffolding adapters. Understanding
how signal specificity is achieved by these receptors remains a
major challenge. An important mechanism of receptor speci-
ficity may be control of the kinetics and/or the magnitude of
downstream signal responses (21). Yet how these are regulated
differentially by RTKs remains unclear.
Gab1 (Grb2-associated binder 1) is a member of a small
group of scaffolding adapters that includes Drosophila melano-
gaster Dos (Daughter of Sevenless) and mammalian Gab2 and
Gab3 (8–10, 25, 30, 47; H. Keilhack, H. Gu, and B. G. Neel,
unpublished data). These proteins contain an amino-terminal
PH domain, several proline-rich sequences, and multiple bind-
ing sites for SH2 domain-containing proteins. Upon stimula-
tion of appropriate cells with any of a number of RTK ligands,
including epidermal growth factor (EGF), hepatocyte growth
factor (HGF), platelet-derived growth factor (PDGF), nerve
growth factor (NGF), and insulin or insulin-like growth factor
1 (IGF-1), Gab1 rapidly becomes tyrosyl phosphorylated (10,
11, 25, 44). Tyrosyl-phosphorylated Gab1 binds multiple signal
relay molecules, including the p85 subunit of phosphatidylino-
sitol 3-kinase (PI3K) (p85), Shc, Grb2, and the protein ty-
rosine phosphatase (PTP) Shp2 (10, 11, 25, 41, 44). Gab1 is
required for signaling by several RTKs, as Gab1-deficient mice
die in utero (at E12.5 to E17.5) with phenotypes similar to
those observed for mice defective in signaling by HGF, PDGF,
or EGF (14, 34). Moreover, primary fibroblasts from Gab1/
embryos exhibit decreased activation of the Erk mitogen-acti-
vated protein kinase pathway in response to EGF, PDGF, and
HGF.
To understand how Gab1 participates in RTK signaling,
the functions of individual Gab1-signal relay molecule in-
teractions and how these interactions affect each other must
* Corresponding author. Mailing address: Cancer Biology Program,
Beth Israel Deaconess Medical Center, HIM 1047, 77 Ave. Louis
Pasteur, Boston, MA 02215. Phone: (617) 667-2823. Fax: (617) 667-
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† Present address: Mouse Biology Program, European Molecular
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be elucidated. Several lines of evidence indicate that Gab1
acts via Shp2 to control Erk activation. Mutants of Gab1
(20) or receptor-Gab1 chimeras (36) that lack Shp2 binding
sites are unable to cause either Erk activation or morpho-
genesis in MDCK cells. In addition, overexpression of de-
letion or point mutants of Gab1 lacking Shp2 binding blocks
EGF-stimulated Erk activation in transient-transfection sys-
tems (2, 3). Furthermore, dominant-negative (PTP-inactive)
mutants of Shp2 block Erk activation in response to stimu-
lation by a wide variety of growth factors (4, 24), many of
which signal through Gab1, and Shp2 mutant fibroblasts
exhibit defective Erk activation in response to most of these
growth factors (35, 38, 39). Although Shp2 appears to act
upstream of Ras in regulating Erk activation (26, 39), its
precise target in this pathway remains unknown. Conceiv-
ably, Shp2 might regulate the phosphorylation of Gab1 or a
Gab1 binding protein. However, total Gab1 tyrosyl phos-
phorylation is unaffected in Shp2 mutant fibroblasts (39),
arguing that, if Shp2 dephosphorylates Gab1, it must target
specific (and a limited number of) sites.
The Gab1-p85 interaction appears to play a distinct but
nonetheless important role in RTK signaling, as it is critical
for PI3K activation in response to stimulation of the NGF
receptor TrkA (11) and the EGF receptor (EGFR) (31).
Schlessinger and colleagues proposed a positive feedback
loop model involving Gab1 and PI3K in EGFR signaling
(31). Initial recruitment of Gab1 by the EGFR is mediated
by two EGFR tyrosyl residues (Y1068 and Y1086) and the
proline-rich Met binding domain on Gab1. This results in
Gab1 tyrosyl phosphorylation and PI3K association which,
in turn, catalyze local production of PI3,4,5P3 (PIP3). PIP3
binds to the Gab1 PH domain, increasing the recruitment of
Gab1 to the plasma membrane and leading to a further
increase in Gab1 tyrosyl phosphorylation and PI3K activa-
tion. This positive feedback loop may be required to gener-
ate a PI3K signal that is sustained sufficiently to elicit bio-
logical effects. Analogous pathways could exist for other
RTKs that signal via Gab1.
This positive feedback model raises the obvious question of
how PI3K signaling is terminated. Here, we show that, in
addition to its role in Gab1-mediated Erk activation, Shp2
attenuates PI3K activation by controlling the phosphorylation
of the p85 binding sites on Gab1 in response to EGF. Inter-
estingly, this regulatory mechanism is RTK specific: PI3K ac-
tivation in response to other growth factors is unaffected or
potentiated by Shp2. Our results show that scaffolding adapt-
ers, such as Gab1, in concert with PTPs such as Shp2, can
control the kinetics, extent, and location of PI3K activation in
response to specific growth factors.
MATERIALS AND METHODS
Antibodies and reagents. Recombinant human EGF was purchased from Up-
state Biotechnology Inc. (Lake Placid, N.Y.). Recombinant human PDGF BB
and IGF-1 were purchased from Life Technologies (Carlsbad, Calif.). Rabbit
polyclonal anti-Gab1 antibodies were raised against a glutathione S-transferase
(GST)–Gab1(238-379) fusion protein. Anti-Shc and anti-Grb2 monoclonal an-
tibodies (MAbs) were purchased from Transduction Laboratories (Lexington,
Ky.). Rabbit polyclonal anti-p85 antibodies were a gift of Lewis C. Cantley (Beth
Israel-Deaconess Medical Center, Boston, Mass.). Anti-phospho-Akt, anti-phos-
pho-Erk, anti-phospho-glycogen synthase kinase 3 (anti-phospho-GSK-3),
and anti-GSK-3 antibodies were purchased from Cell Signaling Technology
(Beverly, Mass.). Anti-EGFR, anti-Shp2, anti-Akt, and anti-GST antibodies
were from Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif.). Antiphosphoty-
rosine MAb (4G10) was from Upstate Biotechnology. A bacterial expression
vector for GST-p85-N-SH2 was kindly provided by Brian S. Schaffhausen (Tufts
University Medical School, Boston, Mass.). The green fluorescent protein
(GFP)-Gab1, hemagglutinin (HA)-tagged wild-type (WT) Gab1, and HA-tagged
Gab1Shp2 mammalian expression constructs were a gift from Christiane R.
Maroun and Morag Park (McGill University, Montreal, Quebec, Canada). Pro-
tein A and protein G-Sepharose were purchased from Pharmacia Biotech (Upp-
sala, Sweden).
Cell lines and culture. 3T3-immortalized fibroblast lines from Shp2 exon 3/
(Shp246-110) and littermate WT mice were described previously (27) and were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum, 100 U of penicillin/ml, and 100 g of streptomycin/
ml. To stably restore Shp2 expression to the Shp2 mutant cells, full-length Shp2
cDNA (6) was inserted into the retroviral plasmid pBabe-puro (22). Phoenix-
Ecotropic packaging cells (a gift of Garry P. Nolan, Stanford University School
of Medicine) were transiently transfected with the Shp2 retroviral construct.
After 24 h, viral supernatants were collected and used to infect Shp2/ cells in
the presence of Polybrene (4 g/ml) for 2 h. Cells were allowed to recover in
normal medium (see above) for 24 h and then selected with puromycin (2 g/ml).
Puromycin-resistant clones were pooled, and Shp2 expression was assessed by
immunoblotting.
A tetracycline-inducible NIH 3T3 cell line that expresses catalytically inactive,
HA-tagged Shp2 was established in this laboratory by transfecting parental NIH
3T3 cells stably expressing the tetracycline transactivator tTA (40) with HA-
tagged Shp2 C459S (C/S) in the vector pTet-Splice (Life Technologies, Inc.).
Cells were maintained in the same growth medium as above plus tetracycline (2
g/ml) and puromycin (2 g/ml). Expression of Shp2 (C/S) protein was very low
in the presence of tetracycline; removal of tetracycline from the growth medium
resulted in expression of Shp2 (C/S) protein at about twice the level of the
endogenous WT Shp2 (see Fig. 3).
293 cells were maintained in DMEM plus 10% fetal bovine serum and anti-
biotic as described above. Transient transfections of HA-tagged WT Gab1 or
Gab1Shp2 expression constructs (10 g) were carried out by the calcium
phosphate method.
For all growth factor stimulation experiments, cells were first starved for 24 h
in DMEM containing 0.2% fetal calf serum and then either exposed to the
appropriate growth factor (50 ng of EGF/ml, 50 ng of PDGF/ml, or 40 ng of
IGF-1/ml) for various times or left unstimulated.
Immunoprecipitation and immunoblotting. Control or growth factor-stimu-
lated cells were lysed for 40 min at 4°C with Triton lysis buffer (20 mM Tris-HCl
[pH 7.5], 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10 mM NaF, 20 mM
-glycerophosphate, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 10 g
of aprotinin/ml, 10 g of leupeptin/ml, 0.5 g of antipain/ml, and 0.5 g of
pepstatin/ml). Cellular debris was removed by centrifugation at 10,000  g for 5
min at 4°C, and lysates (1 mg of total protein) were incubated with the indicated
antibodies for 2 h at 4°C; collected on protein A or protein G-Sepharose; and
washed twice with 1 ml of lysis buffer, twice with 1 ml of high-salt (0.5 M NaCl)
lysis buffer, and twice more with lysis buffer. Immunoprecipitates were resolved
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
transferred to polyvinylidene difluoride (PVDF) membranes, and probed with
the appropriate primary antibodies, followed by secondary sheep anti-mouse,
donkey anti-rabbit, or protein A conjugated to horseradish peroxidase (1:4,000;
Amersham, Little Chalfont, United Kingdom), as indicated. Commercial anti-
bodies were used at the concentrations recommended by their manufacturers.
Anti-Gab1 immunoprecipitations utilized 2 g of antibody/1 mg of total cell
extracts. For p85 immunoblotting, anti-p85 antibodies were used at 1:1,000.
Immunoreactive bands were visualized by enhanced chemiluminescence (ECL)
(Amersham).
Far-Western blots. GST-p85-N-SH2 was purified on glutathione-agarose
beads, as described previously (5). Gab1 immunoprecipitates from control or
EGF-stimulated cell lysates were resolved by SDS-PAGE, transferred to PVDF
membranes, and incubated for 3 h with GST-p85-N-SH2 (1 g/ml), followed by
anti-GST antibodies (1:1,000). Blots were washed and incubated for 2 h with
horseradish peroxidase-conjugated donkey anti-rabbit antibodies (1:4,000), and
signals were detected by ECL.
Akt assays. Lysates from EGF-stimulated WT or Shp2/ cells were subjected
to immunoprecipitation with anti-total Akt antibodies (2 g), as described above,
followed by two additional washes with 1 ml of kinase buffer (20 mM HEPES
[pH 7.6], 2 mM dithiothreitol, 20 mM MgCl2, 20 mM MnCl2, 1 mM EDTA, 1
mM NaF, 20 mM -glycerophosphate, and 0.1 mM Na3VO4). Kinase reactions
were performed at 30°C for 45 min in 20 l of kinase buffer supplemented with
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10 Ci of [-32P]ATP, 50 M ATP, and 1 g of purified GST-GSK-3 as
substrate. Reactions were terminated by the addition of SDS-PAGE sample
buffer (20 l), and reaction mixtures were boiled for 5 min, resolved by
SDS-PAGE, and visualized by autoradiography.
PI3K assays. Anti-Gab1 immunoprecipitates, prepared as described above,
were washed an additional two times with 10 mM HEPES (pH 7.0)–0.5 M LiCl
and twice with 10 mM HEPES (pH 7.0). Washed immunoprecipitates were
subjected to a PI3K assay using crude brain lipids as substrate as described
previously (33). Products were resolved by thin-layer chromatography. Phospha-
tidylserine and PI4,5P2 were phosphorylated by active p110 produced in Sf9 cells
(a gift of Lewis C. Cantley) in the presence of [-32P]ATP and used as markers.
Immunofluorescence microscopy. Cells grown on glass coverslips were trans-
fected with GFP-Gab1 expression vector with Lipofectamine (Gibco BRL), ac-
cording to the manufacturer’s instructions. After 24 h, cells were starved over-
night in DMEM containing 0.2% fetal calf serum. Forty-eight hours
posttransfection, cells were left untreated or stimulated with EGF and were fixed
in 2% paraformaldehyde in phosphate-buffered saline for 30 min at room tem-
perature. GFP fusion proteins were visualized by conventional fluorescence
microscopy.
RESULTS
Shp2 regulates Gab1-p85 association in response to EGF.
Previous studies suggested that Gab1 (3, 25), as well as its
relative Gab2 (7, 8), might be an Shp2 substrate. However,
overall Gab1 tyrosyl phosphorylation is unaffected in immor-
talized fibroblasts expressing a mutant version of Shp2 (39).
Thus, if Shp2 regulates Gab1 tyrosyl phosphorylation, it must
act on a limited number of Gab1 tyrosyl phosphorylation sites.
To begin to test this possibility, we assessed the association of
Gab1 with known binding partners in 3T3-immortalized fibro-
blasts from mice bearing a targeted mutation in Shp2 exon 3
(Shp246-110) and WT controls. Exon 3-deletion (hereafter,
Shp2/) fibroblasts express small amounts of a truncated pro-
tein that lacks the N-terminal SH2 domain of Shp2. Although
this protein has increased catalytic activity (29), it does not
localize appropriately to activated receptors (35, 39) and, in all
cases examined thus far, appears to behave as a hypomorphic
mutant (27, 35, 38, 39, 46; W. Yang, L. Klaman, B. Chen, S. M.
Thomas, E. George, and B. G. Neel, unpublished data).
WT and Shp2/ cells were starved and then stimulated
with EGF or left unstimulated, and Gab1 immunoprecipi-
tates were resolved by SDS-PAGE and immunoblotted with
anti-Shc, anti-Grb2, and anti-p85 antibodies, respectively.
As expected, there was an increase in the association of
Gab1 with each of these signal relay molecules following
EGF stimulation. Compared to WT cells, there was no dif-
ference in the amount of Gab1-associated Shc and possibly
a small decrease in Gab1-associated Grb2 in Shp2/ cells
(Fig. 1A); notably, reprobing the same membrane with anti-
Gab1 antibodies showed that similar amounts of Gab1 were
recovered in each of these lanes. In contrast, EGF-induced
association of p85 with Gab1 was enhanced markedly in
Shp2/ cells (Fig. 1B). Consistent with previous studies
(39), there was no effect of the Shp2 mutation on either total
EGFR or total Gab1 tyrosyl phosphorylation in response to
EGF stimulation (Fig. 1C). Taken together, these results
suggest that Shp2 negatively regulates EGF-induced Gab1-
p85 association.
Activity of the PI3K pathway is enhanced in Shp2/
cells. To begin to assess the downstream consequences of
enhanced Gab1-p85 association, we measured Gab1-associ-
ated PI3K activity in WT and Shp2/ cells. These experi-
ments revealed markedly increased PI3K activity associated
with Gab1 in the absence of normal Shp2 (Fig. 2A). Most of
the phosphotyrosine-associated PI3K activity (which is be-
lieved to represent the activated pool of PI3K) in EGF-stim-
ulated cells is associated with Gab1 (31). Thus, our data sug-
gested that downstream components of the PI3K pathway
might also be increased in Shp2/ cells. Indeed, EGF-in-
duced activation of Akt, as measured by immunoblotting using
antibodies against the two activating phosphorylation sites
(Ser-473 and Thr-308) in Akt (Fig. 2B) or by Akt kinase assays
(Fig. 2C), was increased and sustained in Shp2/ cells com-
pared to WT cells. Importantly, as expected from earlier stud-
ies (35, 38, 39), EGF-induced Erk activation was impaired in
the same cells in which Akt activation was enhanced (Fig. 2B).
Phosphorylation of Ser-9 in GSK-3, a downstream target of
Akt, also was enhanced in the absence of normal Shp2 (Fig.
2D). Collectively, these data show that the enhanced associa-
tion of p85 with Gab1 in response to EGF stimulation of
Shp2/ cells results in increased activity of the PI3K pathway
in these cells.
Inducible overexpression of catalytically inactive Shp2
protein also increases Gab1-p85 association. Shp2/ cells
have been found to act as hypomorphs in all cases studied in
detail thus far (see above). However, these cells express a
truncated, catalytically activated version of Shp2, and so it
remains possible that the increase in EGF-stimulated Gab1-
p85 association in these cells reflected some neomorphic effect
of truncated Shp2. To exclude this possibility and to assess the
role of the catalytic domain of Shp2 in regulating Gab1-p85
association in response to EGF, we made use of a stable NIH
3T3 cell line that expresses an HA-tagged catalytically inactive
(C459S) Shp2 mutant under tetracycline control. Upon re-
moval of tetracycline from the medium (maximal induction),
the Shp2 C/S mutant is expressed at about twice the level of
endogenous Shp2 (Fig. 3A) and competes with it for binding to
Gab1 upon EGF stimulation. Consistent with our findings with
Shp2/ cells, expression of catalytically inactive Shp2 en-
hanced EGF-stimulated association of p85 with Gab1 (Fig.
3B). As in Shp2/ cells, Akt activation also was increased
upon expression of the Shp2 C/S mutant (Fig. 3C).
We also examined the effect of mutating the Shp2 binding
sites on Gab1 on Gab1-p85 association. For these studies,
293 cells were transfected transiently with constructs that
direct expression of either HA-tagged WT Gab1 or an HA-
tagged Gab1 mutant in which the Shp2 binding sites have
been mutated (HA-Gab1Shp2). As shown in Fig. 3D, loss
of Shp2 binding led to increased association of p85 with
Gab1 following EGF stimulation. Thus, our results show
that Shp2 and, in particular, Shp2 catalytic activity nega-
tively regulate p85 binding to Gab1 and thereby PI3K acti-
vation in response to EGF. Moreover, this regulation ap-
pears to be mediated by Shp2 that is bound to Gab1.
Shp2 regulates p85 binding sites on Gab1 in response to EGF.
The increase in p85 binding to Gab1 in Shp2/ cells could be
due to an effect of Shp2 directly on Gab1 binding sites for p85
or an indirect effect of Shp2 on p85 (or conceivably some other
protein that regulates p85 association with Gab1). There are
three potential binding sites for p85 on Gab1 (Tyr-447, -472,
and -589) (11). If Shp2 specifically dephosphorylates Gab1 p85
binding sites, then the phosphorylation of one or more of these
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sites should be increased in Shp2/ cells compared to that in
WT cells following EGF stimulation. Phosphospecific antibod-
ies to these sites are not available. Instead, we used a GST
fusion protein to the N-SH2 domain of p85 (GST-p85-N-SH2)
in far-Western blots to indirectly assess their phosphorylation
status. Gab1 immunoprecipitates prepared from EGF-stimu-
lated WT and Shp2/ cells were resolved by SDS-PAGE,
transferred to a PVDF membrane, incubated with GST-p85-
N-SH2, and probed with anti-GST antibodies. As expected,
there was an increase in GST-p85-N-SH2 binding to immuno-
precipitated Gab1 following EGF stimulation. Moreover this
interaction was enhanced markedly in Gab1 isolated from
Shp2/ cells (Fig. 4A). These data indicate that the ability of
purified GST-p85-N-SH2 to bind directly to Gab1 is increased
in EGF-stimulated cells lacking Shp2. Since GST-p85-N-SH2
binding to Gab1 is dependent on the tyrosyl phosphorylation of
p85 binding sites on Gab1, the most likely explanation for
these findings is that phosphorylation of p85 binding sites on
Gab1 is increased in the absence of Shp2. We also assessed
direct binding of the SH2 domains of Shp2 (GST-Shp2-NC-
FIG. 1. EGF-induced association of p85 with Gab1 is enhanced in Shp2/ cells. (A and B) WT and Shp2/ cells were serum starved for 24 h
and subsequently stimulated with EGF (50 ng/ml) for 5 min or left unstimulated, as indicated. Cell lysates were subjected to immunoprecipitation
with anti-Gab1 antibodies followed by SDS-PAGE and immunoblotting with anti-Shc, anti-Grb2, or anti-p85 antibodies. The same membrane was
stripped and reprobed with anti-Gab1 antibodies to determine the amount of Gab1 protein precipitated from each sample. (C) Unstimulated or
EGF-stimulated cell lysates were subjected to immunoprecipitation with anti-EGFR or anti-Gab1 antibodies followed by SDS-PAGE and
immunoblotting with antiphosphotyrosine (pY) antibodies. IP, immunoprecipitation.
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SH2) to Gab1 immunoprecipitates isolated from WT and
Shp2/ cells after EGF stimulation. Only a minimal increase
in binding was observed, consistent with selective dephosphor-
ylation of the p85 binding sites of Gab1 by Shp2.
Effect of restoring WT Shp2 expression to Shp2/ cells. We
next asked whether reintroduction of WT Shp2 could rescue
the effects of Shp2 deficiency on EGF signaling. Shp2 was
restored to Shp2/ cells by using retroviral gene transduction
FIG. 2. Increased activity of the PI3K pathway in response to EGF stimulation of Shp2/ cells. (A) Serum-starved cells were treated for 5 min
with EGF (50 ng/ml), and cell lysates were subjected to immunoprecipitations with anti-Gab1 antibodies, followed by immune-complex PI3K
activity assays. (B) WT and Shp2/ cells were left unstimulated or stimulated with EGF for the indicated times. Total cellular proteins (50 g)
were resolved by SDS-PAGE and immunoblotted with anti-phospho-Erk or anti-phospho-Akt antibodies that recognize pSer473 or pThr308, as
indicated. The same blot was stripped and reprobed with anti-total Akt and anti-total Erk1/2. (C) Lysates from control or EGF-stimulated cells
were immunoprecipitated with anti-Akt antibodies, and kinase activities were determined with recombinant GST-GSK-3 as a substrate. The
amount of Akt in the immune complexes was assessed by immunoblotting with anti-Akt. (D) The indicated cells were stimulated with EGF as
described for panel C. Total cellular protein (50 g) was subjected to immunoblotting with anti-phospho-GSK-3 antibodies. The blot was then
stripped and reprobed with anti-total GSK-3. IP, immunoprecipitation; MAPK, mitogen-activated protein kinase.
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(see Materials and Methods). Pooled drug-resistant colonies
were tested for Shp2 expression by immunoblotting analysis.
As expected from previous studies (see above), Shp2/
cells expressed a truncated Shp2 protein at lower levels than
did WT cells. Importantly, the pooled clones reexpressed
WT Shp2 at levels comparable to that found in the WT
fibroblasts (Fig. 5A). Reintroduction of Shp2 markedly de-
creased the amount of p85 that associates with Gab1 (Fig.
5B) and also reduced EGF-induced Akt activation (Fig. 5C)
compared to that in Shp2/ cells. These results, together
with those obtained by inducible overexpression of catalyt-
ically inactive Shp2, argue strongly that the increase in EGF-
evoked Gab1-p85 association and activation of PI3K and its
downstream targets in Shp2/ cells is due to the absence of
WT Shp2, rather than to some indirect effect of clonal
selection.
Akt activation in response to other RTKs is not increased
in Shp2/ cells. Gab1 participates in signaling by a variety of
growth factors, as does Shp2. To investigate whether Shp2
negatively regulates PI3K activation in response to other
growth factors, WT and Shp2/ cells were treated with PDGF
or IGF-1, and Akt activation was assessed by immunoblotting
with activation-specific antibodies. Surprisingly, compared to
WT cells, there was no enhancement of PDGF- or IGF-1-
evoked Akt activation in Shp2/ cells (Fig. 6A and B). In-
deed, Akt activation in response to these growth factors actu-
ally was lower in Shp2/ cells. Notably, in the same cells (and
consistent with previous reports; see above), PDGF- and IGF-
1-induced Erk activation levels were substantially diminished
in Shp2/ cells compared to those in WT cells. Similar results
were obtained with fibroblast growth factor stimulation (data
FIG. 3. Increased Gab1-p85 association and elevated Akt activity
in NIH 3T3 cells inducibly overexpressing catalytically inactive (C/S)
Shp2. (A) Inducible Shp2 C/S cells were serum starved overnight in the
presence (Tet) or absence (Tet) of tetracycline before stimulation
with EGF (50 ng/ml) for 5 min. Total cellular proteins (50 g) were
resolved by SDS-PAGE and immunoblotted with anti-Shp2. Note that,
following induction, expression of HA-Shp2 (C/S) was about twice that
of endogenous Shp2. (B) Inducible Shp2 C/S cells were serum starved
and stimulated as described for panel A. Gab1 immunoprecipitates
were analyzed by SDS-PAGE and immunoblotting with anti-p85 an-
tibodies. The blot was then stripped and reprobed with anti-Gab1.
Note that Gab1 associates with both p85	 and p85 in these cells.
(C) Inducible Shp2 C/S cells were serum starved and stimulated as for
panel A. Akt phosphorylation was examined by immunoblotting with
anti-phospho-Akt (Ser-473) antibodies, after which the membrane was
stripped and reprobed with anti-total Akt. (D) 293 cells were tran-
siently transfected with HA-WT Gab1 or HA-Gab1Shp2 constructs.
After 24 h, cells were serum starved overnight and then stimulated with
EGF (50 ng/ml) for 5 min. Cell lysates were subjected to immunopre-
cipitation with anti-HA antibodies followed by SDS-PAGE and immu-
noblotting with anti-p85 antibodies. The blot was then stripped and
reprobed with anti-HA antibodies to ensure comparable loading. IP,
immunoprecipitation.
FIG. 4. Far-Western analysis of Gab1-p85 interaction in WT and
Shp2/ cells. Gab1 immunoprecipitates, prepared from WT and
Shp2/ cells stimulated with EGF or left unstimulated as indicated,
were resolved by SDS-PAGE and transferred to PVDF membranes.
The membranes were incubated with GST-p85-N-SH2 (A) or GST-
Shp2-NC-SH2 (B), followed by anti-GST and secondary antibodies.
Total Gab1 levels in the Gab1 immune complexes are shown at the
bottom. IP, immunoprecipitation.
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not shown). In contrast to our observations for EGF-stimu-
lated cells, association of p85 with Gab1 in response to PDGF
stimulation in Shp2/ cells was not increased; in fact, it ap-
peared to decrease (Fig. 6C). Thus, Shp2 appears to selectively
attenuate PI3K activation in the EGFR pathway.
EGF induces sustained translocation of Gab1 to the
plasma membrane in Shp2/ cells. By binding to PI3,4,5P3,
the PH domain of Gab1 targets the Gab1 protein to the plasma
membrane in a PI3K-dependent manner in response to growth
factor stimulation (18, 19, 31). To investigate whether the
enhanced Gab1-associated p85 and PI3K activity causes in-
creased recruitment of Gab1 to the plasma membrane follow-
ing EGF stimulation, we transiently expressed a Gab1-GFP
fusion protein in WT and Shp2/ cells and monitored its
localization in response to EGF treatment. In unstimulated
cells, Gab1-GFP was distributed diffusely in the cytoplasm.
Upon EGF stimulation, there was a significant increase in the
amount of Gab1-GFP at the plasma membrane. Compared to
WT cells, in Shp2/ cells, there was more Gab1-GFP trans-
located to the plasma membrane at 5 min after EGF treat-
ment, and plasma membrane localization was sustained for
longer times (Fig. 7).
DISCUSSION
The scaffolding adapter Gab1 is critical for signaling by a
number of RTKs (10, 11, 25, 44) and possibly for some cyto-
kine and antigen receptors (13, 25). Upon cell stimulation,
Gab1 becomes tyrosyl phosphorylated on multiple sites and
recruits several signal relay proteins (10, 11, 25, 41, 44). The
precise ways in which these proteins then transduce signals
further downstream remain unclear. Previous studies impli-
cated Gab1-Shp2 association in signaling to the Ras-Raf-Mek-
Erk pathway, whereas interaction of Gab1 with p85 is impli-
cated in PI3K activation. Our work has revealed further
complexity in the interaction of Gab1 with p85 and Shp2.
Specifically, we have found that Shp2 regulates the amount of
p85 that is bound to Gab1 following EGF stimulation and
thereby determines the kinetics and extent of activation of
PI3K and its downstream targets Akt and GSK-3. Surpris-
ingly, this regulation appears to be RTK specific, such that
PI3K activation following PDGF and IGF-1 stimulation is not
increased—indeed, appears to be decreased—in the absence
of Shp2. Thus, the Gab1-Shp2 interaction has distinct func-
tions in cell signaling in response to different growth factors
FIG. 5. Reexpression of WT Shp2 in Shp2/ cells. (A) WT Shp2 expression was restored to Shp2/ cells by retroviral gene transduction (see
Materials and Methods). Pooled puromycin-resistant clones were assessed for Shp2 expression by immunoblotting. The level of Shp2 expression
in WT cells also is shown. Note the N-terminally truncated Shp2 protein in Shp2/ cells and the near-WT levels of WT Shp2 in the reconstituted
cells. (B) The indicated cell lines were serum starved and then stimulated with EGF (50 ng/ml) for 5 min or left unstimulated. Gab1 immuno-
precipitates were subjected to SDS-PAGE and anti-p85 immunoblotting. The levels of Gab1 in the immunoprecipitates were detected by stripping
the membrane and reprobing with anti-Gab1 antibodies. (C) The indicated cell lines were serum starved and stimulated with EGF for the indicated
times or left unstimulated. Phospho-Akt and total Akt were detected by immunoblotting of total cell lysates. IP, immunoprecipitation.
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and may help to determine the specificity of signals delivered
by RTKs.
Previous studies suggested that Gab1 and Gab2 might be
Shp2 substrates (3, 7, 8, 25). Consistent with previous work
(39), however, we observed no difference in total Gab1 tyrosyl
phosphorylation in response to EGF (Fig. 1C) or other growth
factors (data not shown) in the absence of Shp2. Moreover,
Shc association with Gab1 was similar in WT and Shp2/ cells
(Fig. 1A). These findings left open the possibility that Shp2
might act on specific tyrosyl-phosphorylation sites on Gab1.
Indeed, Gab1-associated p85 is increased dramatically in
Shp2/ cells (Fig. 1B). Accordingly, Gab1-associated PI3K
activity is enhanced (Fig. 2A) and PI3K-dependent down-
stream targets (Fig. 2B to D) exhibit increased activation in
response to EGF stimulation of these cells. Analogous results
were obtained by using a cell line that inducibly overexpresses
FIG. 6. PDGF- and IGF-1-evoked Akt activity is not enhanced in Shp2/ cells. (A and B) Starved WT and Shp2/ cells were stimulated with
50 ng of PDGF/ml (A) or 40 ng of IGF-1/ml (B) for the indicated times. Cell lysates were resolved by SDS-PAGE and subjected to immunoblotting
with pSer473-specific Akt or pErk antibodies, as indicated. The membranes were then stripped and reprobed with anti-total Akt or anti-total
Erk1/2 antibodies. (C) WT and Shp2/ cells were serum starved for 24 h and subsequently stimulated with PDGF (50 ng/ml) for 5 min or left
unstimulated, as indicated. Cell lysates were subjected to immunoprecipitation with anti-Gab1 antibodies, followed by SDS-PAGE and immuno-
blotting with anti-p85 antibodies. Total Gab1 levels in the Gab1 immune complexes are shown at the bottom. IP, immunoprecipitation; MAPK,
mitogen-activated protein kinase.
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catalytically inactive Shp2 (Fig. 3). The truncated protein that
is expressed in Shp2/ cells lacks its N-terminal SH2 domain
(35) and cannot bind to Gab1 (39). Furthermore, a Gab1
mutant unable to bind Shp2 exhibits increased p85 binding
compared to that for WT Gab1 following EGF stimulation.
Taken together, these results imply that Shp2 must be re-
cruited to Gab1 and be catalytically active to regulate Gab1-
p85 association. The most likely explanation for these findings
is that, upon recruitment to Gab1, Shp2 is activated by engage-
ment of its N-terminal SH2 domain (1) and then dephospho-
rylates one or more of the PI3K binding sites on Gab1, thereby
regulating Gab1-p85 interaction. Consistent with a direct effect
of Shp2 deficiency on the tyrosyl phosphorylation of p85 sites
on Gab1, far-Western analysis revealed a marked enhance-
ment in the ability of p85 to bind to Gab1 isolated from
Shp2/ cells (Fig. 4A), whereas binding of Shp2 was only
minimally affected (Fig. 4B). Our results clearly exclude the
possibility that enhanced p85 association with Gab1 in the
absence of functional Shp2 reflects an indirect effect of Shp2
deficiency on p85 or another protein that affects p85 binding to
Gab1. However, we cannot exclude the possibility that Shp2
deficiency indirectly affects the ability of Gab1 to bind p85, e.g.,
by leading to another type of modification on Gab1 that affects
binding ability. Direct assessment of the stoichiometry of phos-
phorylation of the p85 binding sites on Gab1 will be required
to demonstrate this unambiguously.
In contrast, Grb2 association with Gab1 appears to be de-
creased slightly but consistently in Shp2/ cells. The physio-
logical significance of this observation remains to be deter-
mined, but notably, Shp2/ (35, 38, 39) (Fig. 2B and 6) and
Gab1/ (14, 34) fibroblasts have defective Ras3Erk pathway
activation in response to EGF and other growth factors. Since
Grb2 binds the Ras exchange factor Sos, it will be important to
determine whether decreased Gab1-Grb2 association contrib-
utes to decreased Ras3Erk activation. The observed decrease
in Gab1-Grb2 interaction has two other potentially interesting
implications. First, since Gab1-Shc interaction and EGFR ty-
rosyl phosphorylation (and presumably kinase activity) are un-
affected by Shp2 deficiency (Fig. 1A and C), these results
suggest that different tyrosine kinases catalyze the phosphory-
lation of distinct sites on Gab1. Indeed, Gab2 is reportedly
phosphorylated by both colony-stimulating factor 1 receptor
and Src family kinases in macrophages (17). More intriguingly,
however, since Gab1-Grb2 binding is decreased in the absence
of Shp2, it is possible that Shp2 regulates (directly or indi-
rectly) the activity of the kinase that phosphorylates the Grb2
binding site(s) on Gab1. Further studies will be required to
address these issues.
Recently, it was reported that the recruitment of Gab1 to the
EGFR initiates a positive feedback loop in which initial tyrosyl
phosphorylation of Gab1 leads to p85 recruitment, PI3K acti-
vation, and PIP3 production, which then leads to further re-
cruitment (and phosphorylation) of Gab1 via PIP3 binding to
the Gab1 PH domain (31). Our data suggest that, by dephos-
phorylating p85 binding sites on Gab1, Shp2 helps to regulate
the Gab1-PI3K positive feedback loop, thereby controlling the
extent, kinetics, and location of PI3K activation in response to
EGF (Fig. 8). Indeed, in the absence of Shp2, EGF induces
sustained translocation of Gab1 to the plasma membrane (Fig.
7). Since Gab1 activation of the Erk pathway also requires
membrane recruitment (and Gab1 signaling to Erk requires
Shp2), Shp2 may contribute to both Erk activation and inacti-
vation as well. However, we do not exclude the possibility that
other mechanisms, such as the recruitment and activation of
FIG. 7. Sustained EGF-induced relocalization of GFP-Gab1 to the plasma membrane in Shp2/ cells. WT and Shp2/ cells were transfected
with a GFP-Gab1 expression vector. Forty-eight hours posttransfection, cells were stimulated with EGF (50 ng/ml) for the indicated times, fixed,
and analyzed by fluorescence microscopy.
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the 5-inositol phosphatase Ship-2 and/or serine/threonine
phosphorylation of Gab1 and/or PI3K, also contribute to neg-
ative regulation of the Gab1-PI3K positive feedback loop. A
recent report also indicated that phosphorylation of Gab1 by
Erk enhances p85 association with Gab1 (45). Importantly, the
increased interaction of p85 with Gab1 in EGF-stimulated
Shp2/ cells cannot be explained by differential Erk activity,
since EGF-evoked Erk activation is diminished in the absence
of functional Shp2 (e.g., Fig. 2B). However, it is possible that
decreased Erk activation may explain or help explain the de-
creased association of p85 with Gab1 in PDGF- and/or IGF-
1-stimulated Shp2/ cells (compared to WT cells).
Although Gab1-Shp2 interaction is critical for regulation of
EGF-evoked PI3K activation, Shp2 is dispensable for, and may
potentiate, PDGF and IGF-1 stimulation of PI3K-dependent
pathways. Notably, unlike the EGFR, the PDGF receptor
(PDGFR) has direct binding sites for p85, and p85 binding to
these sites is believed to provide the major route to PI3K
activation from the PDGFR (15, 43). Previous studies suggest
that there is no preferential dephosphorylation of these sites by
Shp2 (16), which could explain why there is no increase in Akt
activation in response to PDGF in Shp2/ cells. Less clear is
why PDGF-evoked Akt activation appears to be decreased in
these cells. Conceivably, as discussed above, a tyrosine kinase
regulated by Shp2 could contribute to phosphorylation of the
p85 binding sites on the PDGFR. Alternatively, and perhaps
more likely, decreased Ras activation may lead to lower PI3K
activation in response to PDGF, since Ras binds to and acti-
vates the catalytic subunit (p110) of PI3K (32). Like the
EGFR, the IGF-1 receptor lacks direct binding sites for PI3K.
In the IGF pathway, however, insulin receptor substrate (IRS)
proteins, particularly IRS-1, are more important for PI3K ac-
tivation than is Gab1. Previous studies of the role of Shp2 in
regulating insulin or IGF-1 activation of PI3K yielded conflict-
ing results. One group, studying the effects of IRS-1 mutants
that cannot bind Shp2, reported that Shp2 negatively regulates
p85 binding to IRS-1, presumably by dephosphorylating its p85
binding sites (23). Another group demonstrated that expres-
sion of dominant-negative Shp2 attenuates IRS-1-associated
PI3K activity (42). Our results are consistent with the latter
report and suggest that Shp2 is a positive regulator of PI3K
activation by IGF-1 or insulin, at least in fibroblast cell lines.
How and why Shp2 can act as a negative regulator of EGF-
induced PI3K activation and a positive regulator of PI3K ac-
tivation by other RTKs remain topics for future work.
It is increasingly clear that signal thresholds and the tempo-
ral aspects of signaling are important for determining the cel-
lular response. One way that cells can utilize the same (or
similar) signaling pathways to control a wide range of cellular
processes is to vary the amplitude and duration of pathway
activation and to convert this into qualitatively different bio-
logical responses. In perhaps the best studied example, the
EGFR induces transient Erk activation and stimulates prolif-
eration of PC12 cells, whereas the NGF receptor and fibroblast
growth factor receptor evoke a sustained Erk response, culmi-
nating in neuronal differentiation (21). By regulating the extent
and magnitude of p85 association with Gab1 and thereby help-
ing to regulate the extent and kinetics of PI3K activation in
response to some, but not all, RTKs, Shp2 may play an impor-
tant role in directing the varied effects of different growth
factors.
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